ClinicalTrials.gg
WithdrawnNCT00827151838Updated Oct 26, 2021

Bone Mass Accrual in Adolescent Athletes

A Phase 3 interventional study of Estrogen in Amenorrhea and Bone Loss, sponsored by Massachusetts General Hospital. Withdrawn at 1 site in United States. Open to female participants aged 18 Years to 21 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-10-26.

Sponsored by Massachusetts General Hospital · Phase 3, Interventional, and Treatment

How we know

Why this study was withdrawn
The study was not funded

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 21 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies in Amenorrhea with a site in United States — 7 open to participants now, 9 under way, 1 of them phase 3. Amenorrhea · United States.

Enrollment
28th of 30
0 · median 37
Started
2008
the only one that year
Phase 3
5 of 43
1 open now
Registered
15th of 43
by date
Lead sponsor
8 of 43
Massachusetts General Hospital

Among the 43 studies in Amenorrhea with a site in United States, this one is the 28th largest by enrollment of the 30 interventional ones that give a count, is the only one that started in 2008, is one of 5 in phase 3, and was the 15th registered.

Amenorrhea

80 studies on the registry are indexed under Amenorrhea; 17 are open to participants now.

Browse Amenorrhea studies →

Open to participants now

7 of the 43 studies in Amenorrhea with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 13 Amenorrhea studies recruiting now, none (0%) set no upper age limit and 11 (85%) stop at 75 or younger; 8 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 21 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Amenorrhea with a site in United States, or all of them as a file.
02

Study summary

The adolescent and young adult years are a critical window in time for bone mineral accrual. More than 90% of peak bone mass is achieved by 18 years, and data indicate that insults sustained during adolescence and young adulthood may result in permanent deficits in bone accrual. Adult athletes with amenorrhea (AA) have low bone mineral density (BMD) secondary to hypogonadism, associated with increased fracture risk and associated co-morbidities. We will examine whether estrogen replacement will increase BMD and improve measures of bone microarchitecture in adolescents and young women with AA, thus optimizing peak bone mass.

Read the detailed description

Young female athletes 18-21 years old will be randomized to estrogen (and progesterone) with lifestyle modification versus lifestyle modification alone for a 12 month period. Bone density and structure will be assessed over this period. Hormonal evaluations will also be performed.

03

Conditions studied

  • Amenorrhea
  • Bone Loss

Keywords

  • amenorrhea
  • athletes
  • bone loss
  • eumenorrhea
04

Who can participate

Ages eligible
18 Years to 21 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female
  • 18-21 years of age
  • Hypothalamic amenorrhea
  • Greater than or equal to 15 years bone age
  • between 10th-90th percentiles for age

Exclusion criteria

Exclusion Criteria:

  • Use of medications affecting bone metabolism including estrogen/ progesterone, anabolic steroids and except local application of glucocorticoid creams ( of three months necessary prior to study enrollment if medically permissible to discontinue these)
  • Presence of anorexia nervosa or %IBW of \< 85% based on the 50th %ile of for age
  • Spine BMD Z-score \< -3
  • Conditions other than endurance training that may cause amenorrhea including PCOS (clinical or preceding laboratory evidence of hyperandrogenism with amenorrhea)
  • Conditions other than endurance training that may cause bone metabolism to be affected
  • Abnormal TSH, elevated FSH, hematocrit \< 30%
  • Pregnancy

For girls with AA (to be randomized to estrogen and progesterone or no treatment)

  • History of migraines, hypertension, allergy to peanut oil, undiagnosed abnormal genital bleeding, known, suspected or history of breast or genital cancer or estrogen dependent neoplasia, known to progesterone or estrogen or other product ingredients, liver dysfunction or disease
  • LFTs greater than 1.5 times the
  • Family history or personal history of conditions that may increase risk of thromboembolism:

    1. Family history of myocardial infarction or strokes occurring at less than 50 years
    2. Family history of clotting disorders: normal coagulation profile will be necessary for enrollment
  • History of smoking >10 cigarettes a day (history of smoking >14 cigarettes a day is a for estrogen, but we will be more conservative in our exclusion criteria)
  • Personal history of blood clots
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Active comparator
    Estrogen and lifestyle

    Drug: Estrogen

  • No intervention
    Lifestyle

Interventions

  • DrugEstrogensStudies of EstrogensEstrogens pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Estrogen 100 mcg patch twice weekly with 10 days of oral progesterone monthly for 12 months versus no medication

    Also known as: Vivelle-Dot, Prometrium

06

What researchers measure

Primary outcomes

  1. Bone density

    Time frame: One year

07

Study locations

1 site
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2008, a primary completion of May 2011 and a completion of Jan 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2009
First posted
Jan 22, 2009
Start
Dec 2008
Primary completionActual
May 2011
CompletionEst.
Jan 2015
Last update
Oct 26, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 26, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00827151
Responsible party
Madhusmita Misra (Professor Pediatrics, Massachusetts General Hospital) — Principal investigator
First posted
Jan 22, 2009
Start date
Dec 2008
Primary completion
May 2011
Completion
Jan 2015 (estimated)
Last update
Oct 26, 2021

Study contacts

Madhu Misra, MD, MPH
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Estrogens

Start the discussion